Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Quest Diagnostics Inc (DGX) vs Northrop Grumman Corporation (NOC) Price & Performance

Quest Diagnostics IncTrade
Northrop Grumman CorporationTrade

Price performance (Past 24H)

Key statistics

Quest Diagnostics Inc vs Northrop Grumman Corporation — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Northrop Grumman Corporation trades at $575 (market cap $81.78B). The key difference: Northrop Grumman Corporation is far larger — about 3.1× Quest Diagnostics Inc's market cap, and Northrop Grumman Corporation pays the higher dividend (1.63%). Which is the better fit depends on your goals.

DGXNOC
Market Cap
$26.21B$81.78B
Sector
HealthIndustrials
52-Week High
$238.50$768.02
52-Week Low
$173.49$496.02
Enterprise Value
$31.97B$95.77B
Dividend Yield
1.45%1.63%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.

The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.

Northrop Grumman Corporation

Northrop Grumman (NOC) trades at $577.11, down 0.13% on the day, with a bullish technical trend supported by moving averages despite overbought RSI signals. The company reported strong Q2 2026 earnings, beating EPS estimates with a record $105 billion backlog, driven by defense contracts like the Sentinel program. Fundamentals show solid profitability with a 10.48% net income margin and 26.96% ROE, though valuation ratios like P/E of 18.3 are moderate. Recent news highlights a $3 billion missile-interceptor agreement, reinforcing growth prospects.

Outlook remains positive with analyst consensus favoring Buy (57% of ratings) and a $598.57 price target, implying ~4% upside. Key opportunities include sustained defense spending and backlog execution, while risks involve margin pressures from specific programs and geopolitical dependencies. The stock's proximity to its 52-week high suggests cautious optimism amid robust operational performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX

About Northrop Grumman Corporation

Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.

Read more on NOC